Clinical trials: Acne Inversa
Vitiligo, Atopic Dermatitis
An Observational Study of Patients With Dermatologic Disease
TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients.
- Conditions
- Vitiligo, Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa (HS)
- Trial name
- TARGET-DERM+ (NCT07748169)
- Where
- United States
- Volunteers
- 2,000,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Musculoskeletal Infection, Chronic Rhinosinusitis (Diagnosis)
Establishing Personalized Phage Therapy and Its Comparative Cost in Difficult-to-treat Infections (EPHICACI)
EPHICACI is a multicenter, prospective study that continues and expands the monocentric PHAGEFORCE registry initiated at UZ Leuven.
- Conditions
- Musculoskeletal Infection, Chronic Rhinosinusitis (Diagnosis), Persistent Bacteremia, Pulmonary Infection
- Trial name
- EPHICACI (NCT06368388)
- Testing
- Prospective data collection phage therapy, Prospective data collection standard-of-care
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Psoriasis, Eczema/Atopic Dermatitis
Skin-in-Sight: a Longitudinal Cohort Infrastructure for Standardized Remote Monitoring and the Evaluation of Digital Care Innovations in Chronic Skin Diseases
Psoriasis, atopic dermatitis (eczema) and hidradenitis suppurativa are long-term skin conditions that flare and settle over time. Most of what happens to the skin happens at home, between hospital appointments.
- Conditions
- Psoriasis, Eczema/Atopic Dermatitis, Hidradenitis Suppurativa (HS)
- Trial name
- Skin-in-Sight (NCT07804134)
- Where
- 3 sites in Netherlands
- Volunteers
- 1,000 people
- Sponsor
- Medisch Spectrum Twente
Hidradenitis Suppurativa
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- NCT06799000
- Testing
- Remibrutinib Dose A, Remibrutinib Dose B
- Where
- 139 sites in United States, Argentina and 18 more
- Volunteers
- 588 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa (Acne Inversa)
HS ABSCESSES: I&D VS PUNCH DEBRIDEMENT
This randomized-control trial is designed to determine the recurrence rate of HS abscesses following drainage via two methods: I\&D with a linear incision and PD with an 8mm punch biopsy.
- Trial name
- HSPUNCH (NCT06731309)
- Testing
- Punch Debridement, Incision and Drainage
- Where
- Netherlands
- Volunteers
- 72 people
- Sponsor
- Erasmus Medical Center
Hidradenitis Suppurativa
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
This is a study to evaluate the pharmacokinetic (PK) and safety of sonelokimab in adolescent patients with HS.
- Trial name
- NCT06768671
- Testing
- Sonelokimab
- Where
- 18 sites in United States
- Volunteers
- 35 people
- Sponsor
- MoonLake Immunotherapeutics AG
Hidradenitis Suppurativa
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
- Trial name
- NCT06958211
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 107 sites in United States, Belgium and 7 more
- Volunteers
- 573 people
- Sponsor
- Incyte Corporation
Hidradenitis Suppurativa
The Ohio State University Dermatology Biorepository
This study will create and extend a source of clinical specimens for the future study of inflammatory skin disorders.
- Trial name
- NCT03146676
- Where
- United States
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Hidradenitis Suppurativa
Clinical and Biological Characteristics of Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a common and debilitating skin disease that is poorly understood and understudied. As a result, little is known about disease prognosis and few effective treatments exist for this condition.
- Trial name
- NCT03967600
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Hidradenitis Suppurativa, Pediatric Plaque Psoriasis
Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea
Regulatory Post-Marketing Surveillance in hidradenitis suppurativa, pediatric plaque psoriasis and JIA treated with Cosentyx®(secukinumab) in Korea
- Conditions
- Hidradenitis Suppurativa, Pediatric Plaque Psoriasis, Juvenile Idiopathic Arthritis
- Trial name
- NCT07243782
- Testing
- Secukinumab
- Where
- South Korea
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
HİDRADENİTİS SUPPURATİVA
Periodontal Status and Disease Severity in Hidradenitis Suppurativa Patients
This cross-sectional study aims to evaluate the periodontal status of individuals diagnosed with hidradenitis suppurativa (HS) and to compare them with systemically healthy controls.
- Trial name
- NCT07294456
- Testing
- No intervention (observational study)
- Where
- Turkey (Türkiye)
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- Saglik Bilimleri Universitesi
Hidradenitis Suppurativa
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
The purpose of this study is to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants with hidradenitis suppurativa.
- Trial name
- NCT07049575
- Testing
- Ruxolitinib Cream
- Where
- 21 sites in United States
- Volunteers
- 24 people
- Sponsor
- Incyte Corporation
Hidradenitis Suppurativa (HS)
Observational Study Evaluating Long-Term Safety and Effectiveness of Humira in Patients With Hidradenitis Suppurativa
The objective of this study is to evaluate the long-term safety and effectiveness of Humira in patients with Hidradenitis Suppurativa (HS) in real-world clinical practice in Japan.
- Trial name
- NCT03894956
- Where
- 37 sites in Japan
- Volunteers
- 46 people
- Sponsor
- AbbVie
Hidradenitis Suppurativa
Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa
Currently, there is limited evidence showing increased resolution of HS flares with higher doses of intralesional triamcinolone (ILTAC) as well as a difference in side effect profile between the doses.
- Trial name
- NCT04582669
- Testing
- Intralesional Triamcinolone 10 mg/mL, Intralesional Triamcinolone 20 mg/mL, Intralesional Triamcinolone 40 mg/mL
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
Hidradenitis Suppurativa
Therapeutic Effect of Methalazine on 27 Cases of Suppurative Hidradenitis
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory relapsing disease involving the axillae, breast ,groin and anogenital regions. The therapies of the disease are diverse, including medication and surgery.
- Trial name
- NCT06568224
- Testing
- Mesalazine
- Where
- China
- Volunteers
- 27 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Hidradenitis Suppurativa (HS)
Managed Access Programs for AIN457, Secukinumab
The purpose of this registration is to list Managed Access Programs (MAPs) related to AIN457, secukinumab
- Trial name
- NCT05583604
- Testing
- secukinumab
- Sponsor
- Novartis Pharmaceuticals
Down Syndrome, Alopecia Areata
Tofacitinib for Immune Skin Conditions in Down Syndrome
People with Down syndrome (DS) display widespread immune dysregulation, including several immune skin conditions. This study hypothesizes that pharmacological inhibition of the increased interferon (IFN) signaling seen in DS is…
- Conditions
- Down Syndrome, Alopecia Areata, Atopic Dermatitis / Eczema, Hidradenitis Suppurativa
- Trial name
- NCT04246372
- Testing
- Tofacitinib
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of Colorado, Denver
Hidradenitis Suppurativa
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in areas of the skin such as under the breasts, under armpits, inner thighs, groin…
- Trial name
- Intrepid (NCT06468228)
- Testing
- Lutikizumab
- Where
- 279 sites in United States, Argentina and 42 more
- Volunteers
- 1,400 people
- Sponsor
- AbbVie
Hidradenitis Suppurativa (HS)
Botulinum Toxin Blockade of Neuronal Signals to Immune Cells as a Novel Treatment for Hidradenitis Suppurativa
This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease hidradenitis suppurativa (HS).
- Trial name
- Botox in HS (NCT07756346)
- Testing
- Botulinum Toxin A (Allergan, Inc, Irvine CA)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Massachusetts, Worcester
Hidradenitis Suppurativa
A Randomized Controlled Trial Evaluating the Efficacy of Intralesional Triamcinolone in Hidradenitis Suppurativa.
Purpose: To evaluate the effectiveness of intralesional triamcinolone for the treatment of hidradenitis suppurativa (HS) Participants: Patients diagnosed with Hidradenitis Suppurativa that have active inflammatory HS lesions.
- Trial name
- NCT02781818
- Testing
- Triamcinolone Acetonide 10mg/mL, Triamcinolone Acetonide 40mg/mL, Normal Saline
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill